3β,7β-bis-(trimethylsiloxy)-5-androsten-17-one | 56210-85-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β,7β-bis-(trimethylsiloxy)-5-androsten-17-one
• 英文别名: 3beta,7beta-Bis-(trimethylsiloxy)-5-androsten-17-one；(3S,7R,8R,9S,10R,13S,14S)-10,13-dimethyl-3,7-bis(trimethylsilyloxy)-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
• CAS: 56210-85-6
• 化学式: C₂₅H₄₄O₃Si₂
• 分子量: 448.794
• InChiKey: PHNAVJPJRQBDTD-XEYKCJAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.57
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3β,7β-bis-(trimethylsiloxy)-5-androsten-17-one 以83的产率得到17α-ethynylandrost-5-ene-3β,7β,17β-triol
  参考文献：
  名称：

  Method for preparing substituted 3,7-dihydroxy steroids

  摘要：

  本发明涉及制备17-炔基-7-羟基类固醇的过程，例如17-乙炔基-10R，13S-二甲基2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-十六烷基-1H-环戊[a]苯并[3R,7R,17S]-三醇（也称为17α-乙炔基-雄酮-5-烯-3β，7β，17β-三醇），该过程基本上不含有核雌激素受体结合活性的过程杂质。

  公开号：

  US09994608B2
• 作为产物：
  描述：

  雄甾-5-烯-3beta,7beta-二醇-17-酮 以81的产率得到3β,7β-bis-(trimethylsiloxy)-5-androsten-17-one
  参考文献：
  名称：

  Method for preparing substituted 3,7-dihydroxy steroids

  摘要：

  本发明涉及制备17-炔基-7-羟基类固醇的过程，例如17-乙炔基-10R，13S-二甲基2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-十六烷基-1H-环戊[a]苯并[3R,7R,17S]-三醇（也称为17α-乙炔基-雄酮-5-烯-3β，7β，17β-三醇），该过程基本上不含有核雌激素受体结合活性的过程杂质。

  公开号：

  US09994608B2

文献信息

• METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS
  申请人：White Steven K.

  公开号：US20090326251A1

  公开（公告）日：2009-12-31

  The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.

  本发明涉及制备17-炔基-7-羟基类固醇的过程，例如17-乙炔基-10R,13S-二甲基2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-十六烷基-1H-环戊[a]苯并[3R,7R,17S]-三醇（也称为17α-乙炔基-雄甾-5-烯-3β,7β,17β-三醇），其基本上不含有核雌激素受体结合活性的过程杂质。
• SOLID STATE FORMS OF A PHARMACEUTICAL
  申请人：White Steven K.

  公开号：US20090291933A1

  公开（公告）日：2009-11-26

  The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions.

  本发明提供并描述了固态17α-乙炔基-雄烯-5-烯-3β,7β,17β-三醇，包括非晶态和晶态形式以及特定的多晶形式。17α-乙炔基-雄烯-5-烯-3β,7β,17β-三醇的无水物和溶剂物包括I型无水物和IV型和V型溶剂物。本发明还涉及包含处于所述固态形式的17α-乙炔基-雄烯-5-烯-3β,7β,17β-三醇的固体和悬浮制剂以及使用这些制剂治疗高血糖症状，如2型糖尿病和代谢综合症，以及自身免疫性疾病，如类风湿性关节炎，溃疡性结肠炎和1型糖尿病等与炎症相关的疾病的主体或人类患者。本发明还涉及从17α-乙炔基-雄烯-5-烯-3β,7β,17β-三醇的固态形式制备液体制剂的方法以及使用这些制剂治疗所述疾病的方法。
• Patient populations and treatment methods
  申请人：Flores-Riveros Jaime

  公开号：US20100075937A1

  公开（公告）日：2010-03-25

  The invention provides, inter alia, methods to treat, e.g., hyperglycemia or diabetes patients having two or more of a BMI of at least 28 or 29, a fasting insulin level of at least 4 μU/mL or at least 6 μU/mL and optionally (i) a serum MCP1 level of at least about 400 pg/mL or at least about 500 pg/mL. The treatment method includes administering 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol and optionally another compound such as metformin or glyburide. Specific embodiments include use of 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for the treatment of hypercholesterolemia in a patient and a BMI of at least 28 or 29 and optionally hyperglycemia. In these embodiments, the patient will most preferably have a fasting insulin level of at least 4 μU/mL or at least 5 μU/mL.

  本发明提供了治疗高血糖或糖尿病患者的方法，其中患者至少具有以下两种特征之一：BMI至少为28或29，空腹胰岛素水平至少为4μU/mL或至少为6μU/mL，以及可选地（i）血清MCP1水平至少约为400pg/mL或至少约为500pg/mL。治疗方法包括给予17α-乙炔基雄烯-5-烯-3β，7β，17β-三醇和可选的另一化合物，例如二甲双胍或格列苯脲。具体实施例包括使用17α-乙炔基雄烯-5-烯-3β，7β，17β-三醇治疗具有BMI至少为28或29，可选地具有高血糖的患者的高胆固醇血症。在这些实施例中，患者最好具有至少4μU/mL或至少5μU/mL的空腹胰岛素水平。
• Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
  申请人：Harbor Therapeutics, Inc

  公开号：US08309746B2

  公开（公告）日：2012-11-13

  The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.

  该发明涉及制备17-炔基-7-羟基类固醇的方法，例如17-炔基-10R,13S-二甲基2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-十六烷基-1H-环戊[a]苯并[3,7,17-三醇（也称为17α-炔基-雄烯-3β,7β,17β-三醇）]，该方法基本上不含有与核雌激素受体结合活性的工艺杂质。
• CRYSTALLINE ANHYDRATE FORMS OF A PHARMACEUTICAL
  申请人：White Steven K.

  公开号：US20120296105A1

  公开（公告）日：2012-11-22

  The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions.

  本发明提供并描述了固态的17α-乙炔基-雄甾-5-烯-3β,7β,17β-三醇，包括无定形和结晶形式以及特定的多晶形式。17α-乙炔基-雄甾-5-烯-3β,7β,17β-三醇的无水物和溶剂结晶包括I型无水物和IV型和V型溶剂结晶。本发明还涉及含有以所述固态形式存在的17α-乙炔基-雄甾-5-烯-3β,7β,17β-三醇的固态和悬浮剂配方，以及使用这些配方治疗高血糖症状，如2型糖尿病和代谢综合征，以及自身免疫性疾病，如类风湿性关节炎、溃疡性结肠炎和1型糖尿病等与炎症相关的疾病的受试者或人类患者。本发明还涉及从17α-乙炔基-雄甾-5-烯-3β,7β,17β-三醇的固态形式制备液体配方的方法，以及使用这些配方治疗所述的疾病的方法。